Harrow, Inc. Announces Pricing of \$50 Million Senior Unsecured Notes Due 2030

Key Points of the Announcement

• Offering Details: Harrow, Inc. (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, has announced the pricing of a private offering of \$50 million aggregate principal amount of senior unsecured notes due 2030. The notes carry an interest rate of 8.625% per annum.
• Guarantees: The notes will be guaranteed on a senior unsecured basis by Harrow’s existing and future wholly-owned domestic restricted subsidiaries, and any other subsidiaries that guarantee or co-issue any of Harrow’s indebtedness or any subsidiary indebtedness that guarantees the 2030 Notes, subject to certain exceptions.
• Closing Date: The offering is expected to close on March 27, 2026, subject to customary closing conditions.
• Series and Terms: The new \$50 million notes will be issued as additional notes under the same indenture governing the \$250 million senior unsecured notes due 2030 issued on September 12, 2025. The new notes will be treated as a single series with the existing notes and will share the same terms, except for the date of issuance and the issue price.
• Interest and Payment: Interest on the notes will be payable semi-annually in cash, in arrears, on March 15 and September 15. Interest is deemed to have accrued from March 15, 2026, and will be payable beginning September 15, 2026. The new notes are offered at 100.25% of principal amount plus accrued interest from March 15, 2026.
• Use of Proceeds: Harrow intends to use the net proceeds for general corporate purposes, including initiatives to accelerate growth (such as new product launches), funding upcoming product development activities, future strategic business development opportunities, and related investments.
• Investor Eligibility: The offering is only available to “qualified institutional buyers” as defined under Rule 144A of the Securities Act, or to non-“U.S. persons” outside the United States in accordance with Regulation S.
• Legal Status: The notes and related guarantees have not been registered under the Securities Act of 1933 or any state securities laws and cannot be offered or sold in the United States except under applicable exemptions.

Important Shareholder Information

• Potential Share Price Impact: This announcement is potentially price-sensitive. The issuance of new debt, especially at a relatively high interest rate (8.625%), could impact Harrow’s financial leverage and cost of capital. Shareholders should closely monitor how the proceeds are utilized—particularly if they are directed toward growth initiatives or strategic acquisitions—which could materially affect Harrow’s future earnings and share price.
• Forward-Looking Statements: The press release contains forward-looking statements about the completion of the offering, the expected use of proceeds, and potential business developments. These statements are subject to significant risks and uncertainties, including market conditions, completion of final transaction documents, operational changes, and other execution risks. Actual results may differ materially from those projected.
• Risk Factors: Shareholders should note that if risks or uncertainties materialize, or if underlying assumptions are incorrect, Harrow may not be able to complete the transactions as expected, and actual results may diverge significantly from forecasts. Risks are detailed in Harrow’s SEC filings, including their most recent annual report on Form 10-K.
• No Offer/Solicitation: The press release does not constitute an offer to sell or a solicitation to buy any securities. Any offer or solicitation will be made only by means of a confidential offering memorandum to eligible investors.

Company Overview

Harrow, Inc. (Nasdaq: HROW) is a major provider of ophthalmic disease management solutions in North America. The company offers a comprehensive portfolio of products addressing conditions affecting both the front and back of the eye, such as dry eye disease, wet (neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface and retinal diseases. Harrow is committed to delivering safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.

Contact Information

Mike Biega
Vice President of Investor Relations and Communications
[email protected]
617-913-8890

Disclaimer

This article is prepared for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation to buy any securities. The information herein is based on publicly available documents and may contain forward-looking statements that are subject to risks and uncertainties. Investors should consult the company’s official filings with the Securities and Exchange Commission and their financial advisors before making any investment decisions. The author does not undertake any obligation to update or revise this article in light of future events or circumstances.

View HARROW, INC. Historical chart here